PRC
PCRX icon

Pearl River Capital’s Pacira BioSciences PCRX Stock Holding History

Pearl River Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,448
Closed -$247K – 671
2019
Q4 		$247K Buy
+5,448
New +$231K 0.09% 405

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Pearl River Capital's PCRX Position: Q1 2020 in Review

Pearl River Capital sold out of Pacira BioSciences (PCRX) in Q1 2020, closing a stake of 5,448 shares — an estimated $247K sold.

Pearl River Capital first reported a position in PCRX in Q4 2019 and held it in 1 quarter. The position peaked at $247K in Q4 2019. 226 funds tracked by Wall St. Rank hold PCRX as of Q1 2020.

  • Pearl River Capital reported no remaining Pacira BioSciences position as of Q1 2020 after selling out during the quarter.
  • Pearl River Capital sold 5,448 Pacira BioSciences shares in Q1 2020, an estimated $247K.
  • Pearl River Capital first reported a position in Pacira BioSciences in Q4 2019 and held it in 1 quarter.
  • Pearl River Capital's Pacira BioSciences position peaked at $247K in Q4 2019.
  • 226 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2020.

Based on Pearl River Capital's 13F filing for Q1 2020, filed 6 May 2020.